Last reviewed · How we verify
Metformin / clomid / hCG
This combination uses metformin to improve insulin sensitivity, clomiphene citrate to stimulate ovulation, and human chorionic gonadotropin (hCG) to support the luteal phase and early pregnancy in assisted reproductive technology.
This combination uses metformin to improve insulin sensitivity, clomiphene citrate to stimulate ovulation, and human chorionic gonadotropin (hCG) to support luteal phase function and early pregnancy in assisted reproductive therapy. Used for Infertility associated with anovulation or oligo-ovulation, particularly in PCOS, Assisted reproductive technology (ART) / in vitro fertilization (IVF) support.
At a glance
| Generic name | Metformin / clomid / hCG |
|---|---|
| Also known as | Glucophage / clomiphene citrate / choriomon |
| Sponsor | The Egyptian IVF-ET Center |
| Drug class | Combination fertility agent (insulin sensitizer + ovulation inducer + gonadotropin) |
| Modality | Small molecule |
| Therapeutic area | Reproductive Medicine / Fertility |
| Phase | FDA-approved |
Mechanism of action
Metformin reduces insulin resistance and may improve ovulatory function in polycystic ovary syndrome (PCOS). Clomiphene citrate acts as a selective estrogen receptor modulator to promote follicle-stimulating hormone (FSH) secretion and induce ovulation. hCG mimics luteinizing hormone to trigger final oocyte maturation and supports corpus luteum function post-ovulation.
Approved indications
- Infertility associated with anovulation or oligo-ovulation, particularly in PCOS
- Assisted reproductive technology (ART) ovarian stimulation protocols
Common side effects
- Gastrointestinal disturbance (metformin)
- Hot flashes (clomiphene)
- Ovarian hyperstimulation syndrome (OHSS)
- Headache
- Abdominal bloating or discomfort
Key clinical trials
- Different Induction Protocols in PCOS After Clomiphene Citrate Failed Pregnancy in Non-IVF Cycles (PHASE4)
- Metformin for the Treatment of Unexplained Oligozspermia (PHASE4)
- Clomifene Citrate Versus Metformin in First-line Treatment of Infertility in Patients With Polycystic Ovary Syndrome and a Resistance to Insulin (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Metformin / clomid / hCG CI brief — competitive landscape report
- Metformin / clomid / hCG updates RSS · CI watch RSS
- The Egyptian IVF-ET Center portfolio CI